110514-35-7
Chemical Structure
Noribogaine hydrochloride
- CAS No.: 110514-35-7
- Formula:C19H25ClN2O
- Molecular Weight:332.87
IUPAC Name: (6R,6aS,7S,9R,11S)-7-ethyl-6,6a,7,8,9,10,12,13-octahydro-5H-6,9-methanopyrido[1',2':1,2]azepino[4,5-b]indol-2-ol hydrochloride
InChIKey: BFLJLOKFWZLUTR-IMLBMZRZSA-N
SMILES: CC[C@@H]1[C@@]2([H])[C@]3([H])C4=C(CC[N@]2C[C@@](C1)([H])C3)C5=CC(O)=CC=C5N4.Cl
Biological Activity: Noribogaine hydrochloride is an orally active, blood-brain barrier permeable SERT inhibitor (IC50=50-300 nM) and hERG channel blocker. Noribogaine hydrochloride enhances serotonergic transmission, activates the κ-opioid receptor (OPRK) G protein signaling pathway and inhibits β-arrestin recruitment. Meanwhile, Noribogaine hydrochloride blocks the μ-opioid receptor (OPRM) signaling pathway as well as ion channels associated with cardiac repolarization. Noribogaine hydrochloride induces neuritogenesis, upregulates GDNF mRNA expression, and modulates opioid tolerance. Noribogaine hydrochloride reduces alcohol-seeking behavior in experimental animals, and is widely used in studies related to depression, addiction, alcoholism, and cardiotoxicity[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Noribogaine hydrochloride | 99.9% | Noribogaine hydrochloride is an orally active, blood-brain barrier permeable SERT inhibitor (IC50=50-300 nM) and hERG channel blocker. Noribogaine hydrochloride enhances serotonergic transmission, activates the κ-opioid receptor (OPRK) G protein signaling pathway and inhibits β-arrestin recruitment. Meanwhile, Noribogaine hydrochloride blocks the μ-opioid receptor (OPRM) signaling pathway as well as ion channels associated with cardiac repolarization. Noribogaine hydrochloride induces neuritogenesis, upregulates GDNF mRNA expression, and modulates opioid tolerance. Noribogaine hydrochloride reduces alcohol-seeking behavior in experimental animals, and is widely used in studies related to depression, addiction, alcoholism, and cardiotoxicity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Maillet EL, et al. Noribogaine is a G-protein biased κ-opioid receptor agonist. Neuropharmacology. 2015;99:675-688. [Content Brief]
- [2]. Carnicella S, et al. Noribogaine, but not 18-MC, exhibits similar actions as ibogaine on GDNF expression and ethanol self-administration. Addict Biol. 2010;15(4):424-433. [Content Brief]
- [3]. Rodrı Guez P, et al. A Single Administration of the Atypical Psychedelic Ibogaine or Its Metabolite Noribogaine Induces an Antidepressant-Like Effect in Rats. ACS Chem Neurosci. 2020;11(11):1661-1672. [Content Brief]
- [4]. Shi M, et al. A new approach methodology (NAM) for the prediction of (nor)ibogaine-induced cardiotoxicity in humans. ALTEX. 2021;38(4):636-652. [Content Brief]
Keywords
